Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)

NCT05271552 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

151

Enrollment

INDUSTRY

Sponsor class

Conditions

Agitation
Dementia

Interventions

DRUG: BXCL501
DRUG: Matching Placebo

Sponsor

BioXcel Therapeutics Inc

Collaborators

[object Object]